This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Lilly (LLY) Mirikizumab Meets Ulcerative Colitis Study Goal
by Zacks Equity Research
Lilly's (LLY) mirikizumab meets primary endpoint and key secondary endpoints in phase III ulcerative colitis study.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $110.26 in the latest trading session, marking a +1.89% move from the prior day.
The Zacks Analyst Blog Highlights: Netflix, Toyota, AbbVie, Merck and Sinopec
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Netflix, Toyota, AbbVie, Merck and Sinopec
Top Stock Reports for Netflix, Toyota & AbbVie
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Toyota Motor (TM), and AbbVie (ABBV).
Zacks Market Edge Highlights: AbbVie, Innovative Industrial Properties, Weyerhaeuser, Nutrien and Broadcom
by Zacks Equity Research
Zacks Market Edge Highlights: AbbVie, Innovative Industrial Properties, Weyerhaeuser, Nutrien and Broadcom
5 Innovative Companies That Will Pay You Cold Hard Cash
by Tracey Ryniec
Who says you have to own "boring" utilities, insurers and telecoms to get big dividends?
Why AbbVie (ABBV) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
5 Stocks to Watch Amid Continued Expansion in the Biotech Industry
by Kaustav Ghosh
The biotech industry seems poised for further growth due to factors like advancements in drug research and faster regulatory process, making it wise to look at names like AbbVie (ABBV) and Novavax (NVAX)
Why Is AbbVie (ABBV) Down 2.7% Since Last Earnings Report?
by Zacks Equity Research
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biohaven (BHVN) Q4 Earnings Miss, Nurtec Uptake Promising
by Zacks Equity Research
Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.
Reata (RETA) Beats on Q4 Earnings, Submits Bardoxolone NDA
by Zacks Equity Research
Reata (RETA) reports encouraging fourth-quarter results wherein earnings and sales beat estimates. The company files NDA for lead candidate in Alport syndrome. Stock rises.
Pharma Stock Roundup: SNY/GSK & PFE COVID-19 Vaccine Update, MRK's Pandion Buyout
by Kinjel Shah
Sanofi (SNY) & Glaxo (GSK) start phase II study on their COVID-19 vaccine candidate. Merck (MRK) offers to buy Pandion Therapeutics for $1.85 billion
Editas (EDIT) Misses on Q4 Earnings, Beats on Revenues
by Zacks Equity Research
Editas (EDIT) reports wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates. Pipeline development a key focus for the company.
2 Large Cap Stocks to Buy for Income and Growth Amid Tech Volatility
by Benjamin Rains
Investors might want to add a few large cap names outside of the tech world that also provide income through solid dividend yields...
AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Ironwood (IRWD) Q4 Earnings Beat on Solid Linzess Sales
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter. However, outlook for 2021 misses market expectations.
3 Great Blue Chip Dividend Stocks to Buy Now with Dow at Records
by Benjamin Rains
Investors should always be on the lookout for ways to diversify and bolster their portfolios. One great place to start is with large cap stocks that pay solid dividends...
Editas (EDIT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Editas' (EDIT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its CRISPR-based experimental candidate, EDIT-101.
Pharma Stock Roundup: AZN's Q4 Earnings, FDA Approval for LLY & SNY's Drugs
by Kinjel Shah
AstraZeneca (AZN) announces Q4 results. FDA approves Lilly's COVID-19 antibody cocktail & Sanofi's (SNY) Libtayo for a new indication.
AbbVie (ABBV) Inks CAR T Deal, Gets Botox Label Expansion Nod
by Zacks Equity Research
AbbVie (ABBV) signs an agreement to research and develop two new CAR-T cell therapies. The FDA approves label expansion of Botox for pediatric patients.
Sanofi (SNY)/Regeneron's Libtayo Gets FDA Nod for 2nd Indication
by Zacks Equity Research
The FDA approves Sanofi (SNY)/Regeneron's Libtayo for treating patients with advanced/metastatic basal cell carcinoma. The is the second approved indication for the drug in the United States.
The Zacks Analyst Blog Highlights: Exxon Mobil, AbbVie, Caterpillar, Deere & Co and MetLife
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Exxon Mobil, AbbVie, Caterpillar, Deere & Co and MetLife
Q4 Earnings Season Scorecard and Analyst Reports for Exxon, AbbVie & Caterpillar
by Sheraz Mian
We have provided a real-time update on the Q4 earnings season in today's Research Daily, in addition to featuring new research reports on Exxon (XOM), AbbVie (ABBV) and Caterpillar (CAT).
Here is Why Growth Investors Should Buy AbbVie (ABBV) Now
by Zacks Equity Research
AbbVie (ABBV) could produce exceptional returns because of its solid growth attributes.
What Makes AbbVie (ABBV) a New Buy Stock
by Zacks Equity Research
AbbVie (ABBV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.